Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jason Wittes
ROTH
Jason Wittes
Wall Street Analyst
★☆☆☆☆
#2524
on 13Foresight · ranked by our own returns
34%
Success Rate
-8.6%
Average Return
13 of 38 calls profitable · -1697.1% vs benchmark
📈 Across the calls we could measure, roughly 34% of Jason Wittes's ratings turned a profit when each position was held for 1 year — averaging -8.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

28 Buy 0 Hold 0 Sell
Jason's Stock Coverage 39 ratings · 2026-06-20
Company Date Position Consensus Price Target 1-Yr Return
TSE:CRDL
Cardiol Therapeutics
Sep 12, 2025 BUY Strong Buy
+634.8% avg upside
6 analysts
$14.14
839.90% Upside
·
SPRY
ARS Pharmaceuticals
Sep 04, 2025 BUY Strong Buy
+122.5% avg upside
12 analysts
$40.00
314.52% Upside
-30.5%
CV
CapsoVision, Inc.
Sep 03, 2025 BUY Strong Buy
+36.2% avg upside
3 analysts
$6.00
9.14% Downside
+77.8%
LMAT
Lemaitre Vascular
Aug 26, 2025 BUY Strong Buy
+7.8% avg upside
15 analysts
$106.00
12.77% Upside
-2.9%
XAIR
Beyond Air
Aug 20, 2025 BUY Strong Buy
+5812.8% avg upside
10 analysts
$14.00
3788.98% Upside
-76.6%
FBIO
Fortress Biotech
Aug 19, 2025 BUY Strong Buy
+164.2% avg upside
12 analysts
$12.00
301.36% Upside
+10.1%
CMMB
Chemomab Therapeutics
Aug 19, 2025 BUY Strong Buy
+1689.5% avg upside
6 analysts
$36.00
2268.33% Upside
-53.8%
ARAY
Accuray
Aug 13, 2025 BUY Buy
+1689.3% avg upside
9 analysts
$7.00
1912.09% Upside
-71.8%
STXS
Stereotaxis
Aug 11, 2025 BUY Strong Buy
+126.1% avg upside
7 analysts
$5.00
165.97% Upside
-29.9%
ZBH
Zimmer Biomet Holdings
Aug 08, 2025 BUY Buy
+27.6% avg upside
37 analysts
$138.00
56.93% Upside
-9.9%
GMED
Globus Medical
Aug 08, 2025 BUY Strong Buy
+21.0% avg upside
24 analysts
$105.00
32.59% Upside
+37.1%
ENOV
Enovis
Aug 08, 2025 BUY Strong Buy
+216.5% avg upside
37 analysts
$75.00
241.39% Upside
-12.5%
SRTS
Sensus Healthcare
Aug 07, 2025 BUY Strong Buy
+142.0% avg upside
8 analysts
$10.00
258.52% Upside
-36.4%
OFIX
Orthofix Medical
Aug 05, 2025 BUY Strong Buy
+207.1% avg upside
15 analysts
$22.00
132.81% Upside
-0.2%
DFTX
Definium Therapeutics
Aug 04, 2025 BUY Strong Buy
+44.9% avg upside
20 analysts
$36.00
47.05% Upside
+161.0%
IRMD
Iradimed
Aug 04, 2025 BUY Strong Buy
-9.3% avg upside
6 analysts
$72.00
21.96% Downside
+24.3%
ATEC
Alphatec Holdings
Aug 01, 2025 BUY Strong Buy
+112.9% avg upside
22 analysts
$22.00
149.68% Upside
-41.2%
SYK
Stryker
Aug 01, 2025 BUY Strong Buy
+24.0% avg upside
36 analysts
$456.00
48.13% Upside
-19.7%
ALUR
Allurion Technologies
Jul 07, 2025 BUY Strong Buy
+1753.4% avg upside
4 analysts
$16.00
2658.63% Upside
-67.2%
TLSI
TriSalus Life Sciences
May 21, 2025 BUY Strong Buy
+126.7% avg upside
8 analysts
$11.00
169.60% Upside
-50.7%
DERM
Journey Medical Corp
Feb 06, 2025 BUY Strong Buy
+98.3% avg upside
11 analysts
$11.00
76.79% Upside
+67.0%
BWAY
Brainsway
Mar 02, 2022 BUY Strong Buy
-11.7% avg upside
9 analysts
$15.00
0.71% Upside
-75.3%
NVCR
NovoCure
Feb 07, 2022 BUY Strong Buy
+242.4% avg upside
11 analysts
$200.00
1300.58% Upside
+27.1%
BTCY
Biotricity
Jul 01, 2021 BUY Buy
+7767.4% avg upside
4 analysts
$7.00
5697.02% Upside
-50.1%
SE:EKTA.B
Elekta AB
Jan 07, 2021 BUY Sell
+23.4% avg upside
12 analysts
$145.00
198.77% Upside
·
TGTX
TG Therapeutics
Feb 22, 2017 BUY Strong Buy
-34.4% avg upside
19 analysts
$26.00
51.09% Downside
·
VRAYQ
Viewray
Feb 06, 2017 BUY Strong Buy
+558333233.4% avg upside
12 analysts
$11.00
1099999900.05% Upside
+26.5%
MDWD
Mediwound
Nov 28, 2016 BUY Strong Buy
+51.7% avg upside
13 analysts
$11.00
22.85% Downside
-10.3%
INO
Inovio Pharmaceuticals
Nov 07, 2016 BUY Buy
+808.3% avg upside
19 analysts
$12.00
976.19% Upside
-19.2%
CTSO
Cytosorbents
Oct 26, 2016 BUY Strong Buy
+2611.9% avg upside
13 analysts
$20.00
4463.18% Upside
+2.5%
HRTX
Heron Therapeutics
Oct 26, 2016 BUY Strong Buy
+6404.5% avg upside
21 analysts
$41.00
9720.31% Upside
-6.0%
CLDX
Celldex
Oct 10, 2016 BUY Strong Buy
+20.6% avg upside
28 analysts
$16.00
50.68% Downside
-26.2%
PCRX
Pacira Pharmaceuticals
Oct 07, 2016 HOLD Buy
+74.3% avg upside
21 analysts
+5.5%
PALI
Palisade Bio
Oct 04, 2016 BUY Strong Buy
+1347.1% avg upside
15 analysts
$4.00
113.87% Upside
-66.8%
MDXG
MiMedx Group
Sep 12, 2016 BUY Strong Buy
+184.1% avg upside
17 analysts
$12.00
227.01% Upside
+62.4%
REGN
Regeneron
Aug 05, 2016 BUY Strong Buy
+26.9% avg upside
57 analysts
$489.00
19.82% Downside
+10.8%
XTNT
Xtant Medical Holdings
Aug 03, 2016 BUY Strong Buy
+1443.3% avg upside
9 analysts
$10.00
2169.53% Upside
-57.8%
TFX
Teleflex
Jul 29, 2016 BUY Buy
+42.1% avg upside
19 analysts
$168.00
32.37% Upside
+17.4%
SNN
Smith & Nephew Snats
Oct 30, 2015 HOLD Buy
+11.8% avg upside
14 analysts
-11.3%
🔒 34 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Jason Wittes — Frequently Asked Questions
How accurate are Jason Wittes's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Jason's ratings were profitable over a one-year hold, with an average return of -8.5% per rating, or -25.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jason ranked on 13Foresight?
Jason Wittes is currently ranked #2524 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jason cover?
Jason most recently has ratings on TSE:CRDL, SPRY, CV, LMAT, XAIR, FBIO, CMMB, ARAY, STXS, ZBH, GMED, ENOV and 27 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.